Lyell Immunopharma co-led a series A round for the gene therapy developer, which partially exploits UW research.

Outpace Bio, a US-based smart cell therapy developer partially based on research at University of Washington, completed a $30m series A round yesterday backed by WRF Capital, the early-stage investment unit of commercialisation firm Washington Research Foundation. Cellular therapy developer Lyell Immunopharma and venture capital firm Artis Ventures co-led the round, which also attracted Abstract…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.